dc.contributor.author | Davidson, Alexander | |
dc.contributor.author | Raviendran, Nivashinie | |
dc.contributor.author | Murali, Charisma Nair | |
dc.contributor.author | Myint, Phyo Kyaw | |
dc.date.accessioned | 2020-05-04T08:05:01Z | |
dc.date.available | 2020-05-04T08:05:01Z | |
dc.date.issued | 2020-03-31 | |
dc.identifier | 162463077 | |
dc.identifier | bd820d8b-cb05-41ac-ad2c-e702ede7ac89 | |
dc.identifier | 32355839 | |
dc.identifier | 85081973764 | |
dc.identifier | 000522784900138 | |
dc.identifier.citation | Davidson , A , Raviendran , N , Murali , C N & Myint , P K 2020 , ' Managing heart failure with preserved ejection fraction ' , Annals of Translational Medicine , vol. 8 , no. 6 , 395 . https://doi.org/10.21037/atm.2020.03.18 | en |
dc.identifier.issn | 2305-5839 | |
dc.identifier.other | PubMedCentral: PMC7186731 | |
dc.identifier.uri | https://hdl.handle.net/2164/14231 | |
dc.format.extent | 11 | |
dc.format.extent | 248782 | |
dc.language.iso | eng | |
dc.relation.ispartof | Annals of Translational Medicine | en |
dc.subject | Heart failure | en |
dc.subject | heart failure with preserved ejection fraction (HFpEF) | en |
dc.subject | TRIAL | en |
dc.subject | PULMONARY-HYPERTENSION | en |
dc.subject | SPIRONOLACTONE | en |
dc.subject | EXERCISE CAPACITY | en |
dc.subject | PHOSPHODIESTERASE-5 INHIBITION | en |
dc.subject | BETA-BLOCKERS | en |
dc.subject | IRBESARTAN | en |
dc.subject | DIURETICS | en |
dc.subject | R Medicine (General) | en |
dc.subject | General Medicine | en |
dc.subject.lcc | R1 | en |
dc.title | Managing heart failure with preserved ejection fraction | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Medical Education | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.21037/atm.2020.03.18 | |